Cipla Limited
https://www.cipla.com/home
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cipla Limited
Hetero To Debut Biosimilar Actemra, Giving India Grasp On Supplies Security
The availability later this month of Hetero's biosimilar tocilizumab, ostensibly a less pricey product, could place India in a relatively better situation to cope with any demand spurt should another wave of COVID-19 strike. Innovator product Actemra is expected to be in short supply, going by current trends, given the unprecedented worldwide demand.
After Zydus' Historic COVID-19 DNA Vaccine Approval, Inovio To Enter Phase III
Soon after Zydus Cadila won a historic accelerated approval in India for the world’s first plasmid DNA vaccine for human use, in this case against COVID-19, Inovio’s candidate is set to move to Phase III in Brazil. But will the new technology find wide acceptance?
Cipla Resets Biosimilars Interest, Readies Respiratory-Focused JV
Cipla moves beyond in-licensing approach and teams up with CDMO Kemwell to develop and progress respiratory biosimilars. Commercialization of products anticipated post 2025.
Cipla Targets Global Respiratory Biosimilars With Kemwell JV
Cipla is to establish a new company with CDMO Kemwell Biopharma to develop and launch biosimilars for the global market, especially in the respiratory space, where Cipla has built a considerable presence for inhalation products.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Pharmaceuticals
-
Services
- Consulting Services
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- Nutraceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Cipla Gulf FZ LLC
- Cipla Technologies LLC
- InvaGen Pharmaceuticals Inc.
- Mirren Pty, Ltd.